We have located links that may give you full text access.
CASE REPORTS
JOURNAL ARTICLE
Rituximab in the treatment of bullous systemic lupus erythematosus.
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases 2011 April
Rituximab is a CD20 chimeric monoclonal antibody. It was approved by the US Food and Drug Administration for the treatment of relapsed or refractory low-grade or follicular non-Hodgkin lymphoma and for the treatment of moderate to severely active rheumatoid arthritis. It has been used as an off-label treatment in many autoimmune diseases, where B cells play a major role in the pathogenesis. We report a case of successful use of rituximab in the treatment of refractory bullous systemic lupus erythematosus in an African American patient.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app